• FirefoxTry Yahoo Finance on Firefox »
  •  Dow up 0.40% Nasdaq up 0.10%
    {"s" : "^dji,^ixic","k" : "p20","o" : "","j" : ""}
     Dow up 0.40% Nasdaq up 0.10%
    {"s" : "^dji,^ixic","k" : "p20","o" : "","j" : ""}

    Quote Results

    Add Quotes

    SymbolTime & PriceChg & % ChgDay's Low & HighVolumeAvg VolMkt CapChartMore Info
    12:16pm EST 67.435 -1.045 -1.53% 66.97 67.93 7,592,611 11,143,000 13.33B Sparkline Chart Chart, News, Options, Board
    {"s" : "xlv","k" : "t53,l84,c63,p43,g53,h53,v53,j10,c63,l84,p43,a00,a50,b00,b60,g00,h00,t53,v53","o" : "","j" : "c63,l84,p43,t53,v53"}

    Quotes delayed, except where indicated otherwise.

    Recent News

    day and time symbols news headline and source
    Today
    Stock ETFs Mixed As Biotechs Take Ill On A Single Donald Trump Comment at Investor's Business Daily10:44am EST
    David Einhorn’s Investment Guidance at the Robin Hood Conference at Market Realist10:43am EST
    Will the November Jobs Report Delay the Fed’s Rate Hike Urgency? at Market Realist08:06am EST
    The U.K. won’t Brexit — and a bank’s 9 other ‘outrageous’ 2017 predictions at MarketWatch07:11am EST
    Monday December 5, 2016
    Can Donald Trump Make Valeant Stock Great Again? (VRX, XLV) at Investopedia12:25pm EST
    Friday December 2, 2016
    The Fuel for Today’s Reflationary Fire: What You Need to Know at Market Realist02:04pm EST
    Which US Sectors Look Appealing in the Reflationary Environment? at Market Realist10:58am EST
    Keytruda Is Merck’s Immuno-Oncology Business at Market Realist08:04am EST
    The controversial medical association that counts Trump nominee Tom Price among its members at MarketWatch07:32am EST
    Wednesday November 30, 2016
    What Do Analysts Recommend for Boston Scientific? at Market Realist06:30pm EST
    What Are Analysts’ Recommendations for Thermo Fisher Scientific? at Market Realist10:48am EST
    Scrutinizing the HCV Market Based on Genotypes at Market Realist10:04am EST
    Markets Set Chance of Fed Rate Hike at 90% at Market Realist09:38am EST
    Tuesday November 29, 2016
    Analyzing Allergan’s Growth Pharma Plans at Market Realist01:26pm EST
    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17? at Market Realist11:04am EST
    Acthar’s Higher Exposure to Government-Oriented Franchise at Market Realist08:06am EST
    Monday November 28, 2016
    Humira Has Been a Key Growth Driver for AbbVie in 2016 at Market Realist10:05am EST
    How Did Bristol-Myers Squibb’s Virology Segment Perform in 3Q16? at Market Realist10:04am EST
    Friday November 25, 2016
    What Eli Lilly’s hard fall in Alzheimer’s treatment race means for its competitors at MarketWatch07:09am EST
    Thursday November 24, 2016
    This Is Eli Lilly’s Animal Health Segment at Market Realist11:04am EST
    Wednesday November 23, 2016
    Health Care ETFs Fall As Eli Lilly, Juno Add To Troubled Sector's Woes at Investor's Business Daily10:36am EST
    BMY’s Orencia Has Been Approved to Treat Methotrexate-Naive Patients at Market Realist10:04am EST